

TULLY LILLIS

1111 BROADWAY, SUITE 1500
OAKLAND, CA 94607
DIRECT: +1 510 285 1225
TLILLIS@COMPASSLEXECON.COM

Tully Lillis is a Senior Vice President with Compass Lexecon based in Oakland, CA. Mr. Lillis specializes in applying economic and quantitative analysis to areas of competition and antitrust and has extensive experience in consulting to private companies and Federal agencies having led engagement teams in support of experts on a wide variety of complex litigation and regulatory matters. While he has managed case teams in the evaluation of antitrust issues in a variety of contexts, his tenure has seen a particular focus on Private Party Antitrust Litigation, Antitrust Class Action, and Damages as applied to pharmaceuticals, vaccines, and PBMs. His case experience includes, among other things, the application of economics to issues of both single-firm monopolization as well as multi-firm conspiracies involving allegations of reverse settlement payments, product hopping, improper Orange Book listings, bundled product discounts, predatory pricing, and price fixing. Mr. Lillis has substantial institutional knowledge and familiarity of the competitive dynamics, industry data, and regulatory framework within the space. In addition to pharmaceutical litigation, Mr. Lillis's has led analyses of proposed mergers and of the competitive effects of business practices in a variety of industries including biological instrument manufacturing, consumer payment systems, aircraft manufacturing, collegiate and professional sports, energy generation, and electronics.

EDUCATION

BA in Economics (High Distinction), University of California, Berkeley, 2011

PROFESSIONAL EXPERIENCE

Compass Lexecon, Oakland, CA, 2011-present

<i>Senior Vice President,</i>	2025 - Present
<i>Vice President,</i>	2022 - 2025
<i>Senior Economist,</i>	2019 - 2022
<i>Economist,</i>	2014 - 2019
<i>Senior Analyst,</i>	2013 - 2014
<i>Analyst,</i>	2011 – 2013

Fisher Investments, San Mateo, CA, 2011

Marketing Associate, 2011
Junior Associate, 2011

SELECTED CONSULTING EXPERIENCE (PREVIOUS 10 YEARS)

Consultant to branded pharmaceutical manufacturer in a case involving the delay of its product to market due to alleged improper listing of Orange Book patents by competing firm (Liability and Damages), 2024-2025.

Consultant to generic pharmaceutical manufacturer in a case involving the delay of its product to market due to alleged sham litigation (Liability and Damages), 2023-2024.

SELECTED CONSULTING EXPERIENCE (PREVIOUS 10 YEARS, CONT'D)

Consultant to joint defendants in a case involving broad allegations of generic pharmaceutical collusion and price fixing (Liability), 2023-2024.

Consultant to Class Plaintiffs in a case involving delayed generic entry, product hopping, and patent extension strategies for HIV medications (Liability), 2021-2023.

Consultant to Mylan in various cases involving allegations that Mylan entered rebate agreements with pharmacy benefit managers (“PBMs”) for favorable and exclusive formulary placement of Mylan’s EpiPen Auto-injector that had the effect of excluding Sanofi’s rival product, Auvi-Q, from the market and inflated prices to consumers (Liability), 2018-2022.

Co-authored white paper and presented economic analysis to FTC on behalf of manufacturer of life science and clinical instruments concerning its proposed acquisition of a pre-market start-up, 2021-2022.

Consultant to medical device manufacturer in a case alleging its sales relationships included impermissible restraints on competition (Liability), 2021.

Consultant to manufacturer of life science and clinical instruments in a case alleging attempted monopolization through prior firm acquisitions and alleging monopolization in certain upstream IP markets (Liability and Damages), 2020-2021.

Consultant to Branded pharmaceutical manufacturer in a case involving alleged agreements to delay generic entry while it moved the market to an alternate formulation of its blockbuster drug (Damages), 2020.

Consultant to joint defendants in a case involving allegations that brand and generic manufacturers entered into co-promotion agreements amounting to reverse payment settlements of their Paragraph IV patent suits (Class Certification), 2015-2018.

Consultant to Celgene in a case alleging reverse payment settlement agreement with a generic manufacturer (Liability), 2018.

Consultant to Fresenius in a case relating to claims that Akorn, a company Fresenius had agreed to acquire, had suffered a material adverse effect. Evaluated first mover advantage in generic pharmaceutical industry and how delay of entry for generic manufacturers can lead to sustained reduced profits, 2018.

Consultant to a nuclear waste disposal company in a case relating to its proposed acquisition of a Class A waste facility, 2016-2017.

Consultant to Mutual Pharmaceuticals and King Pharmaceuticals in a case alleging that a licensing agreement was a disguised “stand down” payment leading to the delayed availability of generic metaxalone (Liability and Damages), 2014-2017.

Consultant to Teva on its proposed acquisition of Allergan Generics, 2015-2016.

Consultant to generic pharmaceutical manufacturer analysing the NPV of a product development and co-promotion agreement being reviewed by the FTC, 2014-2015

Consultant to generic pharmaceutical manufacturer analysing the net present value of profits flowing from a product development and co-promotion agreement being reviewed by the FTC, 2014-2015